SCHEMBL2300943

SCHEMBL2300943

COc1nc(-c2ccccc2)ccc1COc1ccc(OCC(=O)O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 3/20 0.50
ALOX15 P16050 2/20 0.50
KDM4E B2RXH2 2/20 0.50
HSD17B10 Q99714 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
MAPK1 P28482 1/20 0.50
ACACA Q13085 1/20 0.49
PPARD Q03181 4/20 0.49
PPARG P37231 2/20 0.49
FFAR4 Q5NUL3 1/20 0.47
PPARA Q07869 2/20 0.44
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
PTPN1 P18031 1/20 0.43
PTPN7 P35236 2/20 0.43
FFAR1 O14842 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14931854 0.87 FFAR4 (0.47) ALDH1A1HPGDMAPTALOX15KDM4E
SCHEMBL2298720 0.87 PPARD (0.57) PPARDPPARGPPARAPTPN1FFAR1
SCHEMBL2298241 0.85 FFAR1 (0.48) ALDH1A1HPGDMAPTALOX15KDM4E
SCHEMBL2300444 0.84 PLA2G4B (0.50) TSHRACACAPPARDPPARGFFAR4
SCHEMBL14943922 0.84 FFAR1 (0.54) ALDH1A1HPGDMAPTALOX15KDM4E
SCHEMBL2303659 0.84 CYP1A2 (0.51) ALDH1A1HPGDMAPTALOX15KDM4E
SCHEMBL2304741 0.84 PPARG (0.51) ALDH1A1HPGDMAPTALOX15KDM4E
SCHEMBL2299993 0.81 FFAR4 (0.52) ALOX15ACACAPPARDPPARGFFAR4
SCHEMBL2302108 0.80 FFAR1 (0.66) FFAR1
SCHEMBL14931852 0.79 ACACA (0.46) ALDH1A1HPGDMAPTALOX15KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US claimed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP claimed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US claimed
WO-2016149299-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. (US) 2016-09-22 WO disclosed
US-20160271149-A1 THERAPEUTIC COMPOUNDS THAT SUPPRESS PROTEIN ARGININE METHYLTRANSFERASE ACTIVITY FOR REDUCING TUMOR CELL PROLIFERATION EPINOVA THERAPEUTICS CORP. 2016-09-22 US disclosed
US-8461183-B2 PPAR agonist compounds, preparation and uses GENFIT (FR) 2013-06-11 US disclosed
EP-2310371-B1 PPAR AGONIST COMPOUNDS AND PREPARATION AND USES THEREOF FOR TREATING DIABETES AND/OR DYSLIPIDEMIA GENFIT (FR) 2013-05-15 EP disclosed
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES GENFIT (FR) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195993-A1 PPAR AGONIST COMPOUNDS, PREPARATION AND USES PPARD, PPARA, PPARG ALDH1A1 1483/4885HPGD 1128/4885MAPT 4551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.